Early access of bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Andrei Mariandyshev

Conflict of interest: Dr. Kazennyy has nothing to disclose.

Conflict of interest: Dr. Lounis has nothing to disclose.

Conflict of interest: Dr. Keim reports personal fees from Janssen Pharmaceutical Companies of Johnson & Johnson, outside the submitted work.

Conflict of interest: Dr. Davidaviciene has nothing to disclose.

Conflict of interest: Dr. Vasilyeva has nothing to disclose.